Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

Published:2014-05-24 Issue:1 Volume:15 Page:
ISSN:1471-2474
Container-title:BMC Musculoskeletal Disorders
language:en
Short-container-title:BMC Musculoskelet Disord

Author:

Pritchard Charles H, ,Greenwald Maria W,Kremer Joel M,Gaylis Norman B,Rigby William,Zlotnick Steve,Chung Carol,Jaber Birgit,Reiss William

Publisher

Springer Science and Business Media LLC

Subject

Orthopedics and Sports Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1186/1471-2474-15-177.pdf

Reference18 articles.

1. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006, 54 (9): 2793-2806. 10.1002/art.22025.

2. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, Dougados M, Burmester GR, Greenwald M, Kvien TK, Williams S, Hagerty D, Cravets MW, Shaw T: Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2009, 68 (2): 216-221. 10.1136/ard.2007.085787.

3. Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, Agarwal S, Yin M, Kelman A: Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol. 2010, 37 (5): 917-927. 10.3899/jrheum.090442.

4. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H: Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010, 69 (9): 1629-1635. 10.1136/ard.2009.119933.

5. Rituxan(r) [package insert]. 2013, South San Francisco, CA: Genentech, Inc

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implementation of an Accelerated Infusion Protocol (90-Minute Infusion) of Rituximab and Its Safety in Patients With Autoimmune Rheumatic Diseases at a Tertiary Veterans Affairs Center;Cureus;2024-05-18

2. ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial;Journal of Neurology;2024-04-22

3. The frequency and associated factors of infusion-related reactions to rituximab for patients with rheumatoid arthritis;Interdisciplinary Medical Journal;2023-08-31

4. Effects of an Ocrevus Rapid Infusion Protocol: A Literature Review and Quality Improvement Project;Journal of Infusion Nursing;2023-03

5. Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial;Annals of Clinical and Translational Neurology;2021-02-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3